during august for first 30 days as i've predicted. A complicated process and MSB are being thorough, and as ive said before I almost wouldnt want it to be stopped early so we can have even more data points to potentially support label extentions for ards (bacterial, influenza). agvhd first, label extention to ards eventually (and the other agvhd applications). People arent sure why CHF and CLBP are not at the forefront of meso's mind at the moment, but REM-L is the current gameplay to make the company a commercially viable and sustainable one.
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C, page-75
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
-0.065(6.10%) |
Mkt cap ! $1.141B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | 99.5¢ | $3.340M | 3.302M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 53813 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 59202 | 19 |
View Market Depth
| Last trade - 15.44pm 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |